TNSN91050A1 - Derives dialkoxy-pyridinyl-benzimidazole, procedes en vue de leur preparation, et leur emploi pharmaceutique - Google Patents

Derives dialkoxy-pyridinyl-benzimidazole, procedes en vue de leur preparation, et leur emploi pharmaceutique

Info

Publication number
TNSN91050A1
TNSN91050A1 TNTNSN91050A TNSN91050A TNSN91050A1 TN SN91050 A1 TNSN91050 A1 TN SN91050A1 TN TNSN91050 A TNTNSN91050 A TN TNSN91050A TN SN91050 A TNSN91050 A TN SN91050A TN SN91050 A1 TNSN91050 A1 TN SN91050A1
Authority
TN
Tunisia
Prior art keywords
dialkoxy
pyridinyl
processes
preparation
pharmaceutical use
Prior art date
Application number
TNTNSN91050A
Other languages
English (en)
Inventor
Elof Brandstrom Arne
Lennart Lindberg Per
Elisabeth Sunden Gunnel
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9002206A external-priority patent/SE9002206D0/xx
Priority claimed from SE9002207A external-priority patent/SE9002207D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of TNSN91050A1 publication Critical patent/TNSN91050A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DES COMPOSES NOUVEAUX AYANT LA FORMULE I ET DES SELS PHYSIOLOGIQUEMENT ACCEPTALES DE CEUX-CI, OU R1 E R2, QUI SONT DIFFERENTS, EST CHACUN H, ALKYLE CONTENANT 1 A 4 ATOMES DE CARBONE OU -C(O)-R5 ; OU R5 EST ALKYLE CONTENANT 1 A 4 ATOMES DE CARBONE OU ALKOXY CONTENANT 1 A 4 ATOMES DE CARBONE, ET PARMI R1 ET R2, L'UN EST TOUJOURS SELECTIONE DANS LE GROUPE -C(O)-R5 ; R3 ET R4 SONT LES MEMES OU DIFFERENTS ET PEUVENT ETRE -CH3, -C2H5, -CH2 - , -CH2- , AND -CH2CH2OCH3 OU R3 ET R4 FORMENT ENSEMBLE AVEC LES ATOMES D'OXYGENE ADJACENTS FIXES AU NOYAU PYRIDINE ET AVEC LES ATOMES DE CARBONE DU NOYAU PYRIDINE UN NOYAU, DANS LEQUEL LA PARTIE CONSTITUEE PAR R3 ET R4 EST -CH2CH2CH2-, OU CH2-CH2- OU -CH2 ; AINSI QUE LES INTERMEDIAIRES, LES COMPOSITIONS PHARMACEUTIQUES QUI CONTIENNENT LES DITS COMPOSES COMME INGREDIENT ACTIF, ET L'EMPLOI DES COMPOSES EN MEDECINE
TNTNSN91050A 1990-06-20 1991-06-19 Derives dialkoxy-pyridinyl-benzimidazole, procedes en vue de leur preparation, et leur emploi pharmaceutique TNSN91050A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002206A SE9002206D0 (sv) 1990-06-20 1990-06-20 New compounds
SE9002207A SE9002207D0 (sv) 1990-06-20 1990-06-20 New compounds i

Publications (1)

Publication Number Publication Date
TNSN91050A1 true TNSN91050A1 (fr) 1992-10-25

Family

ID=26660803

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN91050A TNSN91050A1 (fr) 1990-06-20 1991-06-19 Derives dialkoxy-pyridinyl-benzimidazole, procedes en vue de leur preparation, et leur emploi pharmaceutique

Country Status (29)

Country Link
US (1) US5430042A (fr)
EP (1) EP0593463B1 (fr)
JP (1) JP3049367B2 (fr)
CN (1) CN1058213A (fr)
AP (1) AP253A (fr)
AT (1) ATE184602T1 (fr)
AU (1) AU649456B2 (fr)
BG (1) BG97198A (fr)
CA (1) CA2083606C (fr)
CZ (1) CZ279434B6 (fr)
DE (1) DE69131627T2 (fr)
EG (1) EG19752A (fr)
ES (1) ES2140391T3 (fr)
FI (1) FI925767A0 (fr)
HU (1) HUT62882A (fr)
IE (1) IE912026A1 (fr)
IL (1) IL98472A (fr)
IS (1) IS3720A7 (fr)
LV (1) LV10269B (fr)
MA (1) MA22198A1 (fr)
NO (1) NO924650D0 (fr)
NZ (1) NZ238545A (fr)
OA (1) OA09683A (fr)
PL (2) PL166209B1 (fr)
PT (1) PT98036A (fr)
RO (1) RO110497B1 (fr)
TN (1) TNSN91050A1 (fr)
WO (1) WO1991019712A1 (fr)
YU (1) YU104091A (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103776D0 (sv) * 1991-12-19 1991-12-19 Astra Ab New compounds
TNSN95062A1 (fr) * 1994-05-27 1996-02-06 Astra Ab Nouveaux derives dialkoxy-pyridinyle-benzimidazole
DK0723436T3 (da) * 1994-07-08 2001-11-26 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5545661A (en) * 1995-05-16 1996-08-13 Eli Lilly And Company Methods for inhibiting bone loss with bis-pyrone oxovanadium compounds
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6051570A (en) * 1997-05-30 2000-04-18 Dr. Reddy's Research Foundation Benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
CA2295817C (fr) * 1997-07-11 2008-02-12 Eisai Co., Ltd. Procedes d'elaboration de derives pyridiniques
GB9805558D0 (en) * 1998-03-17 1998-05-13 Knoll Ag Chemical process`
NZ510180A (en) * 1998-08-10 2002-11-26 Univ California Prodrugs of the pyridyl-methylsulphonyl-benzimidazole type proton pump inhibitors
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP1469839A2 (fr) * 2002-01-25 2004-10-27 Santarus, Inc. Administration par voie muqueuse d'inhibiteurs de la pompe a protons
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
JP4463103B2 (ja) * 2002-07-19 2010-05-12 ウィンストン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー ベンズイミダゾール誘導体およびプロトンポンプ阻害剤のプロドラッグとしてのその使用
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
EP2112920B1 (fr) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI337877B (en) * 2003-07-18 2011-03-01 Santarus Inc Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
AU2004314693B2 (en) 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20060241037A1 (en) * 2003-10-03 2006-10-26 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
BRPI0507837A (pt) * 2004-02-18 2007-07-10 Allergan Inc métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons
WO2005082337A2 (fr) * 2004-02-18 2005-09-09 Allergan, Inc. Methodes et compositions d'administration de promedicaments d'inhibiteurs de la pompe a protons
TW200606163A (en) * 2004-04-22 2006-02-16 Eisai Co Ltd Imidazopyridine compound
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
WO2006013960A1 (fr) * 2004-08-06 2006-02-09 Eisai R & D Management Co., Ltd. Sels de derive de benzimidazole avec des amines et procede de production de ceux-ci
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (fr) 2006-04-03 2014-03-11 Isa Odidi Dispositif d'administration a liberation commandee comprenant un enrobage organosol
WO2007122686A1 (fr) * 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. Composes benzimidazole
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
RU2467747C2 (ru) 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
WO2008036201A1 (fr) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de pompes à protons comprenant le groupe fonctionnel 1h-imidazo[4,5-b] pyridine
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
JP2009196894A (ja) * 2006-10-13 2009-09-03 Eisai R & D Management Co Ltd スルフィニルベンズイミダゾール化合物またはその塩の製造方法
US20110009624A9 (en) 2006-10-13 2011-01-13 Masato Ueda Benzimidazole compounds having gastric acid secretion inhibitory action
EP2486910A3 (fr) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Appareil comprenant plusieurs chambres et une tête de distribution
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
WO2011080501A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080500A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080502A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
EP2601947A1 (fr) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Combinaison à dose fixe pour le traitement de maladies associées à Hélicobacter pylori
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
AU568441B2 (en) * 1984-09-24 1987-12-24 Upjohn Company, The 2-(pyridylalkenesulfinyl) benzimidazole derivatives
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8500996D0 (sv) * 1985-03-01 1985-03-01 Haessle Ab Method of treatment
US4738975A (en) * 1985-07-02 1988-04-19 Takeda Chemical Industries, Ltd. Pyridine derivatives, and use as anti-ulcer agents
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
NZ222495A (en) * 1986-11-21 1991-04-26 Haessle Ab Benzimidazole derivatives and pharmaceutical compositions
DE3722810A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag Substituierte benzimidazole, verfahren zu deren herstellung, diese enthaltende pharmazeutische zubereitungen und deren verwendung
HU886738D0 (en) * 1987-10-30 1990-02-28 Haessle Ab Process for the preparation of pharmaceutical compositions against osteoporosis containing 2-pyridinyl-methyl-(sulfinyl or thio)-benzimidazoles
AU2817989A (en) * 1987-12-11 1989-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel benzimidazole derivatives
WO1989011479A1 (fr) * 1988-05-25 1989-11-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouveaux composes fluores d'alkoxyde
SE8804628D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New compounds
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles

Also Published As

Publication number Publication date
AU649456B2 (en) 1994-05-26
WO1991019712A1 (fr) 1991-12-26
CZ279434B6 (cs) 1995-04-12
AP253A (en) 1993-05-03
IL98472A (en) 1995-08-31
IE912026A1 (en) 1992-01-01
DE69131627D1 (de) 1999-10-21
JP3049367B2 (ja) 2000-06-05
HU9204034D0 (en) 1993-03-29
MA22198A1 (fr) 1992-04-01
US5430042A (en) 1995-07-04
OA09683A (en) 1993-05-15
AU8061791A (en) 1992-01-07
AP9100286A0 (en) 1991-07-31
NO924650L (no) 1992-12-02
NZ238545A (en) 1993-08-26
JPH05507714A (ja) 1993-11-04
EG19752A (en) 1996-01-31
LV10269B (en) 1995-10-20
FI925767A (fi) 1992-12-18
BG97198A (bg) 1993-12-24
HUT62882A (en) 1993-06-28
PL297295A1 (fr) 1992-07-13
CS189391A3 (en) 1992-06-17
RO110497B1 (ro) 1996-01-30
ATE184602T1 (de) 1999-10-15
DE69131627T2 (de) 2000-04-27
CA2083606C (fr) 2001-08-21
FI925767A0 (fi) 1992-12-18
LV10269A (lv) 1994-10-20
CN1058213A (zh) 1992-01-29
PL165898B1 (pl) 1995-02-28
NO924650D0 (no) 1992-12-02
EP0593463B1 (fr) 1999-09-15
YU104091A (sh) 1994-01-20
EP0593463A1 (fr) 1994-04-27
CA2083606A1 (fr) 1991-12-21
ES2140391T3 (es) 2000-03-01
IS3720A7 (is) 1991-12-21
PL166209B1 (pl) 1995-04-28
IL98472A0 (en) 1992-07-15
PT98036A (pt) 1992-03-31
PL297294A1 (fr) 1992-07-13

Similar Documents

Publication Publication Date Title
TNSN91050A1 (fr) Derives dialkoxy-pyridinyl-benzimidazole, procedes en vue de leur preparation, et leur emploi pharmaceutique
TNSN91049A1 (fr) Benzimidazoles substitues, procedes en vue de leur preparation, et leur emploi pharmaceutique
TNSN96161A1 (fr) Derives de la quinoleine et de quinazoline nouveaux procede pour leur preparation et formulations pharmaceutiques les contenant.
CA2102454A1 (fr) Derives de l'erythromycine, leur procede de preparation, leur application comme medicaments
FR2392986A1 (fr) Nouveaux composes de phtalazine et composition pharmaceutique les contenant
DK121385D0 (da) 3-acyl-2-oxindol-1-carboxamid-forbindelser og farmaceutiske praeparater
IL95103A0 (en) Pyrimidine nucleosides,their preparation and pharmaceutical compositions containing them
LV12766A (lv) Composition of l-dopa esters
BE900345A (fr) Composition pharmaceutique ophtalmiques a base d'un derive d'acide phenylacetique.
JPS57206695A (en) Novel derivative of c-076 compound
TNSN88041A1 (fr) NOUVEAUX β-D-PHENYL THIOXYLOSIDES, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
BE903183A (fr) Nouveaux derives du benzonorbornene, leurs procedes de preparation et composition medicamenteuse et cosmetique les contenant
Razdan et al. Drugs derived from cannabinoids. 2. Basic esters of nitrogen and carbocyclic analogs
BE1000201A4 (fr) Composes antibiotiques, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2424259A1 (fr) Esters de l'acide ((trifluoromethyl-5 pyridyloxy-2)-4 phenoxy)-4 pentene-2 oique utiles comme herbicides
FR2612517B1 (fr) Derives de benzoxazine, procedes de preparation de ces derives et compositions pharmaceutiques les contenant
CA2107485A1 (fr) Nouveaux derives d'ellipticine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR890012942A (ko) 5-치환된 오르니틴 유도체
TNSN92073A1 (fr) Derives d'ammonium quaternaire de (+) et (-) 10- (1-azabicyclo [2,2,2] oct-3-yl-methyl) -10-h-phenothiazine, compositions pharmaceutiques les contenant et procede pour leur preparation
Boyd et al. Insecticide toxicology. Augmented susceptibility to carbaryl toxicity in albino rats fed purified casein diets
FR2367056A1 (fr) Compositions biocides a base de derives aryles d'hydrazone pour lutter contre les maladies des plantes
FR2449689A1 (fr) Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique
DE69001004D1 (de) Zusammensetzung gegen leberkrankheiten.
OA09665A (fr) Esters d'aminoacides de l'hydroquinone, leur procédé de préparation et compositions pharmaceutiques ou cosmétiques les contenant
BE1002181A3 (fr) 3-(2-haloalkyl)-1,4-oxathiines et 2-(2-haloalkyl)-1,4-dithiines, de meme que le traitement de la leucemie et des tumeurs avec ces substances.